Abdominal Aortic Aneurysm Market Insights, Epidemiology and Market Forecast-2030
(Albany, US) DelveInsight launched a new report on Abdominal Aortic Aneurysm Market Insights, Epidemiology and Market Forecast-2030
Some of the key facts of the report1. Abdominal Aortic Aneurysm affects approximately 2% to 8% of the population older than 60 years.2. Abdominal Aortic Aneurysm prevalence increases rapidly in men after age 55 years and in women after age 70 years.3. Abdominal Aortic Aneurysm is the most commonly due to degeneration from arteriosclerosis. It comprises 65% of all aortic aneurysms; 90% occur below the renal arteries.4. The studies have shown an increased Abdominal Aortic Aneurysm incidence worldwide, ranging from 4.2% to 11% per year.5. Every year, 200,000 people in the US are diagnosed with an abdominal aortic aneurysm.
Key benefits of the report1. Abdominal Aortic Aneurysm market report covers a descriptive overview and comprehensive insight of the Abdominal Aortic Aneurysm epidemiology and Abdominal Aortic Aneurysm market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Abdominal Aortic Aneurysm market report provides insights on the current and emerging therapies.3. Abdominal Aortic Aneurysm market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Abdominal Aortic Aneurysm market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Abdominal Aortic Aneurysm market.
Request for sample pages
“Abdominal Aortic Aneurysm is more common in men than in women.”
The golden standard of Abdominal Aortic Aneurysm treatments is invasive interventions either with open surgical repair (OS) or endovascular aneurysm repair (EVAR). The concept of medical treatment is to prevent the disease from rupture and avoid surgical treatment by preventing aneurysm enlargement or even reducing aneurysm size. Matrix metalloproteinases (MMP) are structurally related metalloendopeptidases that can degrade the extracellular matrix, and is thought to play essential roles. There are many proposed pharmacological treatments, including ?-blockers, angiotensin-converting enzyme inhibitor (ACE inhibitors), angiotensin-receptor blocker (ARB), statins, macrolides and, doxycycline, an inhibitor of the MMP. Specific treatment is based on the age, overall health, medical history, extent of the disease, signs and symptoms, tolerance of specific medications, procedures, or therapies.
Unfortunately, no pharmacotherapy has been realized despite considerable effort, and several challenges need to be addressed. First, it is possible that appropriate drug targets in Human Abdominal Aortic Aneurysm have not been identified. Indeed, many animal studies have assessed the effects of interventions in limiting Abdominal Aortic Aneurysm development rather than the effects on pre-established Abdominal Aortic Aneurysm. Also, the experimental opportunities for analyzing human Abdominal Aortic Aneurysm specimens have decreased in recent years. Continued efforts, including the appropriate use and interpretation of animal models, and full utilization of human samples are essential to gain a better understanding of Human Abdominal Aortic Aneurysm pathophysiology and pathogenesis. Second, it is essential for pharmacotherapy to be sufficiently concentrated at the site. Third, there is a possibility that the heterogeneity of human Abdominal Aortic Aneurysm might not be fully appreciated or taken into account when testing therapeutic agents since patients with Abdominal Aortic Aneurysm are heterogeneous in terms of their characteristics, clinical history, and genetic background.Therefore, it may be better to stratify Abdominal Aortic Aneurysm patients according to the predominant biological activities; towards this end, identification of biomarkers accurately reflect the biological activity. If researchers can optimize therapeutic regimens for individual patients using biomarkers (personalized medicine), the patient may be able to achieve more effective outcomes with pharmacologic therapy and prevent or slow Abdominal Aortic Aneurysm progression. The companies are currently working toward this indication to meet the needs of the current Abdominal Aortic Aneurysm market, and subsequently redress the current issues. Pipeline drugs in clinical development are designed to address this unmet need in the Abdominal Aortic Aneurysm treatment. The other factors that shall further expedite the growth of the Abdominal Aortic Aneurysm market include increasing morbidity rate and increasing awareness about available treatments during the forecast period (2020–2030). A better understanding of disease pathogenesis will also contribute to the development of novel Abdominal Aortic Aneurysm therapeutics.
The launch of the emerging therapies is expected to significantly impact Abdominal Aortic Aneurysm treatment scenario in the upcoming years:-Drugs covered1. Metformin Glucophage2. TicagrelorAnd many others
The key players in Abdominal Aortic Aneurysm market are:
1. Merck Serono2. AstraZenecaAnd many others
Table of contents1. Report Introduction2. Executive Summary3. SWOT Analysis4. Abdominal Aortic Aneurysm Market Overview at a Glance5. Abdominal Aortic Aneurysm Disease Background and Overview6. Abdominal Aortic Aneurysm Epidemiology and Patient Population7. Abdominal Aortic Aneurysm Country- Wise Epidemiology7.1. United States7.2. EU-57.2.1. Germany7.2.2. France7.2.3. Italy7.2.4. Spain7.2.5. United Kingdom7.3. Japan8. Abdominal Aortic Aneurysm Treatment & Medical Practices9. Patient Journey10. Key Abdominal Aortic Aneurysm Emerging Therapies10.1. Metformin Glucophage: Merck Serono10.2. Ticagrelor: AstraZeneca11. Attribute Analysis12. Abdominal Aortic Aneurysm Market Size13. 7MM Abdominal Aortic Aneurysm Country-Wise Market Analysis14.1. United States14.2. Germany14.3. France14.4. United Kingdom14.5. Spain14.6. Italy14.7. Japan15. Market Access and Reimbursement16. Market Drivers17. Market Barriers18. Appendix19. Abdominal Aortic Aneurysm Report Methodology20. DelveInsight Capabilities21. Disclaimer22. About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
[email protected]+919650213330SOURCE DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/